Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)
Annexon宣布关于真实世界证据研究的积极顶线结果，该研究比较了Anx005治疗与静脉注射免疫球蛋白(Ivig)或血浆置换(市盈率)在格林-巴利综合症(Gbs)治疗中的效果，研究对象为匹配患者群体。
